Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
June 03 2024 - 7:00AM
Corcept Therapeutics Incorporated (NASDAQ: CORT), a
commercial-stage company engaged in the discovery and development
of medications to treat severe endocrinologic, oncologic, metabolic
and neurologic disorders by modulating the effects of the hormone
cortisol, today announced that the results from GRACE, the Phase 3
trial of its proprietary selective cortisol modulator relacorilant
in patients with hypercortisolism (Cushing’s syndrome), will be
presented at the Endocrine Society (ENDO) annual meeting in Boston
(June 3) and the Heart in Diabetes (HiD) conference in Philadelphia
(June 7).
ENDO 2024, Boston Convention &
Exhibition CenterLate-Breaking Poster
Presentation: Open-label Results From GRACE, A Phase 3
Double-blind, Randomized-withdrawal Study Of The Selective
Glucocorticoid Receptor Modulator Relacorilant For The Treatment Of
Endogenous Hypercortisolism (Cushing Syndrome)Date &
Time: Monday, June 3, 2024, 12:00-1:30 pm
ETPresenter: Rosario Pivonello, MD, PhD, Principal
Investigator of the GRACE study and Professor of Endocrinology at
Università Federico II di Napoli, ItalySession:
P108 - Late-Breaking Poster Presentations: Day 3
8th Heart in Diabetes Conference, Hilton
Penn’s Landing Oral Presentation:
Hypercortisolism Impact on Hypertension and Hyperglycemia and
BeyondDate & Time: Friday, June 7,
2024, 3:50-4:00 pm ETPresenter:
Ralph DeFronzo, MD, chief of the Diabetes Division and professor of
medicine at UT Health San AntonioSession:
Hypercortisolism Implication to Cardiorenal & Metabolic
Diseases
Oral Presentation: Medical
Treatment of Hypercortisolism with Relacorilant: Final Results of
the Phase 3 GRACE StudyDate & Time: Friday,
June 7, 2024, 4:00-4:20 pm
ETPresenter: Rosario Pivonello, MD, PhD, Principal
Investigator of the GRACE study and Professor of Endocrinology at
Università Federico II di Napoli, ItalySession:
Hypercortisolism Implication to Cardiorenal & Metabolic
Diseases
Each of the above presentations will be
available on Corcept.com following the event.
About RelacorilantRelacorilant
is a selective cortisol modulator that binds to the glucocorticoid
receptor but does not bind to the body's other hormone receptors.
Corcept is studying relacorilant in a variety of serious disorders
in addition to Cushing’s syndrome, including ovarian, adrenal and
prostate cancer. Relacorilant is proprietary to Corcept and is
protected by composition of matter, method of use and other
patents. Relacorilant has orphan drug designation in the United
States and the European Union for the treatment of Cushing’s
syndrome.
About Corcept TherapeuticsFor
over 25 years, Corcept’s focus on cortisol modulation and its
potential to treat patients with a wide variety of serious
disorders has led to the discovery of more than 1,000 proprietary
selective cortisol modulators. Corcept is conducting advanced
clinical trials in patients with hypercortisolism, solid tumors,
amyotrophic lateral sclerosis (ALS) and liver disease. In February
2012, the company introduced Korlym®, the first medication approved
by the U.S. Food and Drug Administration for the treatment of
patients with Cushing’s syndrome. Corcept is headquartered in Menlo
Park, California. For more information, visit Corcept.com.
Forward-Looking
StatementsStatements in this press release, other than
statements of historical fact, are forward-looking statements based
on our current plans and expectations that are subject to risks and
uncertainties that might cause our actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include, but are not limited to, our
ability to operate our business; risks related to the study and
development of Korlym, relacorilant, dazucorilant, miricorilant and
our other product candidates, including their clinical attributes,
regulatory approvals, mandates, oversight and other requirements;
and the scope and protective power of our intellectual property.
These and other risks are set forth in our SEC filings, which are
available at our website and the SEC’s website.
In this press release, forward-looking
statements include those concerning: relacorilant, including its
clinical attributes and potential to become a treatment for
patients with Cushing’s syndrome or any other disorder, regulatory
oversight of relacorilant, its commercial prospects and the scope
and protective power of our intellectual property. We disclaim any
intention or duty to update forward-looking statements made in this
press release.
CONTACTInvestor
inquiries:ir@corcept.comMedia inquiries:communications@corcept.com
www.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From May 2024 to Jun 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Jun 2023 to Jun 2024